State-of-the-art review on AL amyloidosis in Western Countries: Epidemiology, health economics, risk assessment and therapeutic management of a rare disease

Amyloidosis is the term to define a broad array of rare protein misfolding syndromes. Among them, light chain (AL) amyloidosis is the most common, affecting roughly 10 people per million/year. The core purpose of the present literature review is to shed light on the academic and clinical knowledge o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood reviews Jg. 59; S. 101040
Hauptverfasser:	Sabinot, Alice, Ghetti, Gianni, Pradelli, Lorenzo, Bellucci, Stefania, Lausi, Antonella, Palladini, Giovanni
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Elsevier Ltd 01.05.2023
Schlagworte:	AL amyloidosis Amyloidosis - diagnosis Amyloidosis - epidemiology Amyloidosis - etiology Epidemiology Humans Immunoglobulin Light-chain Amyloidosis - diagnosis Immunoglobulin Light-chain Amyloidosis - epidemiology Immunoglobulin Light-chain Amyloidosis - therapy Light-chain amyloidosis PRISMA guidelines Quality of Life Rare Diseases Risk Assessment Risk-staging Systematic literature review cTnI PR PS BNP LDex CyBorDM dLFC Epidemiology HD-Dex UK cTnT Risk-staging PFS US PRISMA guidelines BorD AL amyloidosis Bor MS AL IT ER ES MDex EU SF36-v1 AT SF36-v2 NCI DaraLDex ASCT IMiD NL Systematic literature review SES N/A RS NR CyBorD FR L N QoL HDM SF36 BU NT-proBNP T NRes MPredDex VGPR DaraBorDex CA GE SR eGFR GI OS SW CI GR m MPred PMP TBor y Light-chain amyloidosis HD HR-QoL
ISSN:	0268-960X, 1532-1681, 1532-1681
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Amyloidosis is the term to define a broad array of rare protein misfolding syndromes. Among them, light chain (AL) amyloidosis is the most common, affecting roughly 10 people per million/year. The core purpose of the present literature review is to shed light on the academic and clinical knowledge on the condition, encompassing its i) epidemiology, ii) economic burden, and iii) quality of life consequences. The areas of interest are Europe and North America. Literature search was primarily performed on Embase® and finally integrated with additional, deemed eligible, sources. Pre-defined PICOS criteria were employed for the inclusion and exclusion processes. A total of 64 studies were comprehensively included in the current literature review as compliant with the inclusion criteria. The results were presented according to the outcomes of interest and eventually triangulated and compared to available literature studies. A broad picture on the main aspects of AL amyloidosis is delivered.
AbstractList	Amyloidosis is the term to define a broad array of rare protein misfolding syndromes. Among them, light chain (AL) amyloidosis is the most common, affecting roughly 10 people per million/year. The core purpose of the present literature review is to shed light on the academic and clinical knowledge on the condition, encompassing its i) epidemiology, ii) economic burden, and iii) quality of life consequences. The areas of interest are Europe and North America. Literature search was primarily performed on Embase® and finally integrated with additional, deemed eligible, sources. Pre-defined PICOS criteria were employed for the inclusion and exclusion processes. A total of 64 studies were comprehensively included in the current literature review as compliant with the inclusion criteria. The results were presented according to the outcomes of interest and eventually triangulated and compared to available literature studies. A broad picture on the main aspects of AL amyloidosis is delivered.Amyloidosis is the term to define a broad array of rare protein misfolding syndromes. Among them, light chain (AL) amyloidosis is the most common, affecting roughly 10 people per million/year. The core purpose of the present literature review is to shed light on the academic and clinical knowledge on the condition, encompassing its i) epidemiology, ii) economic burden, and iii) quality of life consequences. The areas of interest are Europe and North America. Literature search was primarily performed on Embase® and finally integrated with additional, deemed eligible, sources. Pre-defined PICOS criteria were employed for the inclusion and exclusion processes. A total of 64 studies were comprehensively included in the current literature review as compliant with the inclusion criteria. The results were presented according to the outcomes of interest and eventually triangulated and compared to available literature studies. A broad picture on the main aspects of AL amyloidosis is delivered. Amyloidosis is the term to define a broad array of rare protein misfolding syndromes. Among them, light chain (AL) amyloidosis is the most common, affecting roughly 10 people per million/year. The core purpose of the present literature review is to shed light on the academic and clinical knowledge on the condition, encompassing its i) epidemiology, ii) economic burden, and iii) quality of life consequences. The areas of interest are Europe and North America. Literature search was primarily performed on Embase® and finally integrated with additional, deemed eligible, sources. Pre-defined PICOS criteria were employed for the inclusion and exclusion processes. A total of 64 studies were comprehensively included in the current literature review as compliant with the inclusion criteria. The results were presented according to the outcomes of interest and eventually triangulated and compared to available literature studies. A broad picture on the main aspects of AL amyloidosis is delivered.
ArticleNumber	101040
Author	Pradelli, Lorenzo Bellucci, Stefania Palladini, Giovanni Ghetti, Gianni Sabinot, Alice Lausi, Antonella
Author_xml	– sequence: 1 givenname: Alice surname: Sabinot fullname: Sabinot, Alice email: a.sabinot@adreshe.com organization: AdRes HEOR s.r.l., Turin, Italy – sequence: 2 givenname: Gianni surname: Ghetti fullname: Ghetti, Gianni email: g.ghetti@adreshe.com organization: AdRes HEOR s.r.l., Turin, Italy – sequence: 3 givenname: Lorenzo surname: Pradelli fullname: Pradelli, Lorenzo email: l.pradelli@adreshe.com organization: AdRes HEOR s.r.l., Turin, Italy – sequence: 4 givenname: Stefania surname: Bellucci fullname: Bellucci, Stefania email: sbellucc@its.jnj.com organization: Janssen-Cilag Italia, Cologno Monzese, Italy – sequence: 5 givenname: Antonella surname: Lausi fullname: Lausi, Antonella email: alausi1@its.jnj.com organization: Janssen-Cilag Italia, Cologno Monzese, Italy – sequence: 6 givenname: Giovanni surname: Palladini fullname: Palladini, Giovanni email: giovanni.palladini@unipv.it organization: Università di Pavia, Pavia, Italy
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/36697295$$D View this record in MEDLINE/PubMed
BookMark	eNqFkc1uEzEURi1URNPCC7BAXrLoBHs844wrNlVUfqRILADBzvLYd5qbztjBdoryLjwsDiksuigbW7K_Y-t-54yc-OCBkJeczTnj8s1m3o8R5jWrxeGANewJmfFW1BWXHT8hM1bLrlKSfT8lZyltGGNKyMUzciqkVItatTPy63M2GaowVHkNlYmZRrhD-EmDp1craqb9GNCFhImip98gZYieLsPO54iQLun1Fh1MGMZws7-gazBjXlOwwYcJbbqgEdMtNSlBShP4TI13tHwVzRZ2GS2djDc38OcqDNTQaCJQhwlMgufk6WDGBC_u93Py9d31l-WHavXp_cfl1aqyTctzWRfMSjG0vXOdYkI52TfGuJaDLfO2thESHC9tcOiEstBD0_VdVxvR8h6EOCevj-9uY_ixKzPqCZOFcTQewi7peiGVUlLVqkRf3Ud3_QRObyNOJu7130ZLoD4GbAwpRRj-RTjTB216ow_a9EGbPmorUPcAsli8YCgtGxwfR98eUSgFFXNRJ4vgLTiMYLN2AR_HLx_gdkSP1oy3sP8f_BvKqMiE
CitedBy_id	crossref_primary_10_3390_jcdd12030104 crossref_primary_10_7759_cureus_83278 crossref_primary_10_1002_joa3_70068 crossref_primary_10_1016_j_blre_2024_101207 crossref_primary_10_1515_cclm_2023_0326 crossref_primary_10_1016_j_annder_2025_103345 crossref_primary_10_1038_s41598_025_09498_7 crossref_primary_10_1182_blood_2024026676 crossref_primary_10_1016_j_kint_2025_05_010 crossref_primary_10_1242_dmm_052230 crossref_primary_10_1136_openhrt_2024_003124 crossref_primary_10_1038_s44386_025_00015_4 crossref_primary_10_7759_cureus_91334 crossref_primary_10_3390_life14010042 crossref_primary_10_1080_16078454_2025_2476254 crossref_primary_10_3389_fimmu_2023_1203425
Cites_doi	10.3324/haematol.2018.205336 10.1056/NEJMc1917321 10.3816/CLML.2010.n.006 10.1080/03007995.2017.1297930 10.1182/blood-2014-04-570010 10.1016/j.cardfail.2017.07.365 10.1182/blood-2019-124980 10.2147/CEOR.S207127 10.1182/blood-2021-152675 10.1016/j.recesp.2019.12.017 10.1038/s41375-019-0400-5 10.1182/blood-2020-137036 10.1097/CCO.0000000000000881 10.1016/S0016-5085(10)61689-7 10.1200/JCO.2011.38.5724 10.1016/j.clml.2019.09.558 10.1182/blood-2012-12-473066 10.1080/13506129.2017.1411796 10.2217/cer-2017-0100 10.1111/j.1468-1331.2010.03215.x 10.1016/j.blre.2019.100636 10.1002/joa3.12376 10.1200/JCO.20.01285 10.1111/bjh.12677 10.1111/bjh.12973 10.1200/JCO.2004.03.029 10.1182/blood-2021-154277 10.1001/jama.2020.5493 10.1002/jha2.562 10.1038/s41375-018-0370-z 10.1038/s41375-020-1006-7 10.1182/bloodadvances.2018016402 10.1182/bloodadvances.2020003782 10.1182/blood.V128.22.3586.3586 10.1182/blood-2021-151804 10.1016/j.jval.2017.08.927 10.1111/ejh.13472 10.1182/blood-2016-11-751628 10.1038/s41408-020-00355-6 10.1007/s40271-017-0273-5 10.1182/blood.V120.21.1786.1786 10.1007/s00392-019-01490-2 10.1111/bjh.16198 10.1182/blood-2015-01-620302 10.1056/NEJMra023144 10.1056/NEJMoa2028631 10.1186/1471-2458-12-974 10.1016/j.mayocp.2018.08.041 10.1111/ejh.13552 10.1007/s12288-018-0937-x 10.1182/blood-2021-152099 10.1186/s13023-016-0564-2 10.1182/blood.V118.21.992.992 10.4081/itjm.2019.1149 10.1182/blood.V126.23.190.190 10.1016/S0140-6736(15)01274-X 10.1080/13506129.2021.1898365 10.1111/ejh.13554 10.1097/HS9.0000000000000681 10.1016/S2152-2650(21)02153-4 10.1038/s41408-021-00529-w 10.1038/s41572-018-0034-3 10.1111/bjh.12286 10.1016/j.clml.2015.07.201 10.1038/s41408-020-0321-6 10.1080/14656566.2016.1274971 10.1182/blood-2018-06-858951 10.1080/13506129.2018.1536043 10.1182/blood.2020006913 10.1182/blood-2020-140708 10.1136/heartjnl-2016-310704 10.1182/blood.V128.22.4448.4448 10.1080/13506129.2016.1208081 10.1371/journal.pmed.1000097
ContentType	Journal Article
Copyright	2023 The Authors Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Copyright_xml	– notice: 2023 The Authors – notice: Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
DBID	6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1016/j.blre.2023.101040
DatabaseName	ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1532-1681
ExternalDocumentID	36697295 10_1016_j_blre_2023_101040 S0268960X23000012
Genre	Journal Article Review
GroupedDBID	--- --K --M .1- .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 23N 4.4 457 4CK 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABGSF ABJNI ABMAC ABMZM ABUDA ABWVN ABXDB ACDAQ ACGFS ACIEU ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADUVX AEBSH AEHWI AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AGRDE AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG COF CS3 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEB HMK HMO HVGLF HZ~ IHE J1W KOM KQ8 M29 M41 MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSU SSZ T5K UHS WUQ Z5R ~G- ~HD 6I. AACTN AAFTH AAIAV ABLVK ABYKQ AFCTW AFKWA AJBFU AJOXV AMFUW DOVZS LCYCR RIG 9DU AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8
ID	FETCH-LOGICAL-c451t-c470c63f5bdd89039d6b4aad51ec3675c436ed10261e839cebe48b882a351be33
ISICitedReferencesCount	15
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000982686800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0268-960X 1532-1681
IngestDate	Sun Sep 28 00:54:34 EDT 2025 Thu Apr 03 07:06:01 EDT 2025 Sat Nov 29 07:24:53 EST 2025 Tue Nov 18 21:34:03 EST 2025 Fri Feb 23 02:36:56 EST 2024 Tue Oct 14 19:35:10 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Keywords	cTnI PR PS BNP LDex CyBorDM dLFC Epidemiology HD-Dex UK cTnT Risk-staging PFS US PRISMA guidelines BorD AL amyloidosis Bor MS AL IT ER ES MDex EU SF36-v1 AT SF36-v2 NCI DaraLDex ASCT IMiD NL Systematic literature review SES N/A RS NR CyBorD FR L N QoL HDM SF36 BU NT-proBNP T NRes MPredDex VGPR DaraBorDex CA GE SR eGFR GI OS SW CI GR m MPred PMP TBor y Light-chain amyloidosis HD HR-QoL
Language	English
License	This is an open access article under the CC BY license. Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c451t-c470c63f5bdd89039d6b4aad51ec3675c436ed10261e839cebe48b882a351be33
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
OpenAccessLink	https://www.clinicalkey.com/#!/content/1-s2.0-S0268960X23000012
PMID	36697295
PQID	2769996929
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_2769996929 pubmed_primary_36697295 crossref_primary_10_1016_j_blre_2023_101040 crossref_citationtrail_10_1016_j_blre_2023_101040 elsevier_sciencedirect_doi_10_1016_j_blre_2023_101040 elsevier_clinicalkey_doi_10_1016_j_blre_2023_101040
PublicationCentury	2000
PublicationDate	May 2023 2023-05-00 20230501
PublicationDateYYYYMMDD	2023-05-01
PublicationDate_xml	– month: 05 year: 2023 text: May 2023
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England
PublicationTitle	Blood reviews
PublicationTitleAlternate	Blood Rev
PublicationYear	2023
Publisher	Elsevier Ltd
Publisher_xml	– name: Elsevier Ltd
References	Wechalekar, Schonland, Kastritis, Gillmore, Dimopoulos, Lane (bb0285) 2013; 121 Zumbo, Sadeghi-Alavijeh, Hawkins, Fontana (bb0250) 2017; 18 Palladini, Schonland, Merlini, Milani, Jaccard, Bridoux (bb0065) 2021; 5 Davis, Fine (bb0170) 2020; 36 Escher, Senoner, Doerler, Zaruba, Messner, Mussner-Seeber (bb0145) 2020; 109 Hari, Lin, Asche, Ren, Yong, Luptakova (bb0455) 2018; 25 Merlini, Bellotti (bb0005) 2003; 349 Ravichandran, Lachmann, Wechalekar (bb0165) 2020; 382 Hemminki, Li, Försti, Sundquist, Sundquist (bb0310) 2012; 12 Palladini, Milani, Riva, Basset, Foli, Merlini (bb0270) 2015; 126 Acevedo, Doros, Szalat, Sloan, Sarosiek, Sanchorawala (bb0195) 2019; 134 (bb0040) 2021 (bb0035) 2021 Quock, Yan, Tieu, D’Souza, Broder (bb0360) 2019; 11 Mahmood, Venner, Sachchithanantham, Lane, Rannigan, Foard (bb0410) 2014; 166 Moumas, Desport, Lacombe, Gombert, Goujon (bb0325) 2010; 17 Lousada (bb0380) 2020; 15 Abbink, Brink, Roeloffzen, Poddighe, Minnema (bb0070) 2021; 138 Sanchorawala, McCausland, Lo, White, Bayliss, Guthrie (bb0350) 2016; 128 Sidiqi, Al Saleh, Leung, Jevremovic, Aljama, Gonsalves (bb0440) 2020; 10 Palladini, Milani, Merlini (bb0450) 2020; 136 Muchtar, Gertz, Kumar, Lacy, Leung, Buadi (bb0155) 2020; 106 Sattianayagam, Gibbs, Wechalekar, Lachmann, Gilbertson, Philip (bb0315) 2010; 138 Grogan, Dispenzieri, Gertz (bb0030) 2017; 103 Matsuda, Gono, Morita, Katoh, Kodaira, Ikeda (bb0385) 2011; 18 Quock, Yan, Chang, Guthrie, Broder (bb0365) 2018; 7 Muchtar, Therneau, Larson, Gertz, Lacy, Buadi (bb0420) 2019; 33 Sanchorawala (bb0475) 2022; 6 Warsame, Kumar, Carrie, Morie, Lacy, Francis (bb0275) 2015; 100 Wechalekar, Gillmore, Hawkins (bb0025) 2015; 387 Staron, Zheng, Doros, Connors, Mendelson, Joshi (bb0095) 2021; 11 López-Sainz, Hernandez-Hernandez, Gonzalez-Lopez, Domínguez, Restrepo-Cordoba, Cobo-Marcos (bb0150) 2021; 74 Zhang, Cherepanov, Romanus, Kumar, Hughes (bb0200) 2019; 19 Lilleness, Doros, Ruberg, Sanchorawala (bb0130) 2020; 188 Abdallah, Dispenzieri, Muchtar, Buadi, Kapoor, Lacy (bb0140) 2021; 5 Hwa, Gertz, Kumar, Lacy, Buadi, Dingli (bb0415) 2019; 33 Staron, Connors, Zheng, Doros, Sanchorawala (bb0015) 2020; 10 Isath, Correa, Siroky, Mohammed, Chahal, Padmanabhan (bb0355) 2020; 36 Szalat, Sarosiek, Havasi, Brauneis, Sloan, Sanchorawala (bb0465) 2021; 35 Kumar, Dispenzieri, Lacy, Hayman, Buadi, Colby (bb0295) 2012; 30 Taduru, Roy, Taneja, Ramakrishnan, Grover, Samanta (bb0370) 2017; 23 Kyle, Gertz (bb0020) 1995; 32 Palladini, Schönland, Merlini, Milani, Jaccard, Bridoux (bb0060) 2021; 138 Kastritis, Fotiou, Theodorakakou, Dialoupi, Migkou, Roussou (bb0125) 2020; 28 Palladini, Sachchithanantham, Milani, Gillmore, Foli, Lachmann (bb0265) 2015; 126 Fotiou, Kallianos, Theodorakakou, Ntanasis-Stathopoulos, Migkou, Malandrakis (bb0110) 2021; 5 Brink, Minnema (bb0160) 2020 McCausland, White, Yokota, Quock, Guthrie, Bayliss (bb0335) 2017; 130 Muchtar, Gertz, Kumar, Lacy, Dingli, Buadi (bb0245) 2017; 129 Kastritis, Leleu, Arnulf, Zamagni, Cibeira, Kwok (bb0405) 2020; 38 Vaxman, Dispenzieri, Muchtar, Gertz (bb0430) 2020; 40 Palladini, Milani (bb0470) 2022; 34 Jimenez-Zepeda, Reece, Rigo, Gogna, Kong, Hu (bb0085) 2021; 21 McCausland, Quock, Guthrie, White, Bayliss (bb0330) 2017; 20 Moher, Liberati, Tetzlaff, Altman (bb0055) 2009; 6 Palladini, Schönland, Merlini, Milani, Jaccard, Bridoux (bb0115) 2020; 136 McCausland, White, Guthrie, Quock, Finkel, Lousada (bb0240) 2017; 11 Dittrich, Benner, Kimmich, Siepen, Veelken, Kristen (bb0185) 2019; 104 Merlini, Dispenzieri, Sanchorawala, Schönland, Palladini, Hawkins (bb0235) 2018; 4 Jiang, Chen, Liu, Li, Lu, Fu (bb0230) 2018; 34 Jimenez-Zepeda, Reece, Rigo, Gogna, Kong, Hu (bb0485) 2022; 3 Rutten, Raymakers, Hazenberg, Nienhuis, Vellenga, Minnema (bb0210) 2018; 25 Michael, Kastritis, Delimpassi, Michalis, Repoussis, Kyrtsonis (bb0320) 2010; 10 Di Giovanni, Gustafson, Adamson, Delgado (bb0395) 2020; 36 Palladini, Merlini, Milani, Hajek, Bergantim, Joao (bb0120) 2020 Lilleness, Ruberg, Mussinelli, Doros, Sanchorawala (bb0190) 2019; 133 Gertz (bb0220) 2018; 8 Wechalekar, Cibeira, Gibbs, Jaccard, Kumar, Merlini (bb0480) 2022; 1-15 Rizio, White, Mccausland, Quock, Guthrie, Yokota (bb0050) 2018; 11 Nelson, Ramdial, Bashir, Saini, Hosing, Popat (bb0075) 2021; 138 Lee, Tay, Duggan, McCulloch, Neri, Bahlis (bb0135) 2021; 106 Pinney, Smith, Taube, Lachmann, Venner, Gibbs (bb0290) 2013; 161 Mohty, Duhamel, Magne, Lavergne, Bordessoule, Aboyans (bb0215) 2018; 39 Quock, Yan, Chang, Guthrie, Broder (bb0225) 2018; 2 Staron, Zheng, Doros, Connors, Sanchorawala (bb0090) 2021; 138 Bayliss, McCausland, Guthrie, White (bb0340) 2017; 12 Lane, Rannigan, Foard, Wechalekar, Gibbs, Pinney (bb0305) 2011; 118 Kastritis, Roussou, Gavriatopoulou, Migkou, Gkougkoutsi, Pamboukas (bb0300) 2012; 120 Angelini, Zanco, Castellani, Di Francesco, Della Barbera, Vescovo (bb0390) 2019; 13 Schulman, Connors, Weinberg, Mendelson, Joshi, Shelton (bb0180) 2020; 105 Kastritis, Palladini, Minnema, Wechalekar, Jaccard, Lee (bb0400) 2021; 385 Kyle, Larson, Kurtin, Kumar, Cerhan, Therneau (bb0205) 2019; 94 Falk (bb0010) 2013; 164 Rizzo, Avci, Dallemagne, Vercruyssen, Dewilde, Meuleman (bb0100) 2021 Zampieri, Cappelli, Allinovi, Olivotto, Antonioli, Tassetti (bb0105) 2021; 28 Weiss, Lund, Bjorkholm, Cohen, Dember, Landgren (bb0255) 2016; 128 (bb0435) 2021 Al Hamed, Bazarbachi, Bazarbachi, Malard, Harousseau, Mohty (bb0045) 2021; 11 Palladini, Hegenbart, Milani, Kimmich, Foli, Ho (bb0280) 2014; 124 Milani, Basset, Nuvolone, Benigna, Rodigari, Lavatelli (bb0460) 2020; 10 Dispenzieri, Gertz, Kyle, Lacy, Burritt, Therneau (bb0375) 2004; 22 Cohen, Sathyanath, Ravichandran, Law, Manwani, Foard (bb0425) 2020; 136 Lin, Gao, Cooke, Berg, Labotka, Faller (bb0445) 2017; 33 Shu, Lo, Phillips, Sun, Seldin, Berenbaum (bb0345) 2016; 23 Gertz, Dispenzieri (bb0175) 2020; 324 Rosengren, Carlson (bb0080) 2021 Wechalekar, Wechalekar, Mahmood, Youngstein, Coyne, Foard (bb0260) 2015; 15 Lee (10.1016/j.blre.2023.101040_bb0135) 2021; 106 Kastritis (10.1016/j.blre.2023.101040_bb0400) 2021; 385 Kyle (10.1016/j.blre.2023.101040_bb0020) 1995; 32 Al Hamed (10.1016/j.blre.2023.101040_bb0045) 2021; 11 McCausland (10.1016/j.blre.2023.101040_bb0330) 2017; 20 Mohty (10.1016/j.blre.2023.101040_bb0215) 2018; 39 Kastritis (10.1016/j.blre.2023.101040_bb0125) 2020; 28 Lin (10.1016/j.blre.2023.101040_bb0445) 2017; 33 Szalat (10.1016/j.blre.2023.101040_bb0465) 2021; 35 Warsame (10.1016/j.blre.2023.101040_bb0275) 2015; 100 Rizio (10.1016/j.blre.2023.101040_bb0050) 2018; 11 Palladini (10.1016/j.blre.2023.101040_bb0060) 2021; 138 Hari (10.1016/j.blre.2023.101040_bb0455) 2018; 25 Staron (10.1016/j.blre.2023.101040_bb0095) 2021; 11 Quock (10.1016/j.blre.2023.101040_bb0365) 2018; 7 Lilleness (10.1016/j.blre.2023.101040_bb0130) 2020; 188 Wechalekar (10.1016/j.blre.2023.101040_bb0260) 2015; 15 Sattianayagam (10.1016/j.blre.2023.101040_bb0315) 2010; 138 Davis (10.1016/j.blre.2023.101040_bb0170) 2020; 36 Merlini (10.1016/j.blre.2023.101040_bb0005) 2003; 349 Muchtar (10.1016/j.blre.2023.101040_bb0155) 2020; 106 Fotiou (10.1016/j.blre.2023.101040_bb0110) 2021; 5 Rutten (10.1016/j.blre.2023.101040_bb0210) 2018; 25 Pinney (10.1016/j.blre.2023.101040_bb0290) 2013; 161 Sanchorawala (10.1016/j.blre.2023.101040_bb0350) 2016; 128 Moumas (10.1016/j.blre.2023.101040_bb0325) 2010; 17 Merlini (10.1016/j.blre.2023.101040_bb0235) 2018; 4 Isath (10.1016/j.blre.2023.101040_bb0355) 2020; 36 (10.1016/j.blre.2023.101040_bb0040) 2021 Palladini (10.1016/j.blre.2023.101040_bb0270) 2015; 126 Vaxman (10.1016/j.blre.2023.101040_bb0430) 2020; 40 Muchtar (10.1016/j.blre.2023.101040_bb0245) 2017; 129 Grogan (10.1016/j.blre.2023.101040_bb0030) 2017; 103 Staron (10.1016/j.blre.2023.101040_bb0090) 2021; 138 Zumbo (10.1016/j.blre.2023.101040_bb0250) 2017; 18 Sanchorawala (10.1016/j.blre.2023.101040_bb0475) 2022; 6 Moher (10.1016/j.blre.2023.101040_bb0055) 2009; 6 Weiss (10.1016/j.blre.2023.101040_bb0255) 2016; 128 Matsuda (10.1016/j.blre.2023.101040_bb0385) 2011; 18 Kyle (10.1016/j.blre.2023.101040_bb0205) 2019; 94 Palladini (10.1016/j.blre.2023.101040_bb0450) 2020; 136 Milani (10.1016/j.blre.2023.101040_bb0460) 2020; 10 Jimenez-Zepeda (10.1016/j.blre.2023.101040_bb0485) 2022; 3 McCausland (10.1016/j.blre.2023.101040_bb0240) 2017; 11 (10.1016/j.blre.2023.101040_bb0035) 2021 Quock (10.1016/j.blre.2023.101040_bb0225) 2018; 2 Zampieri (10.1016/j.blre.2023.101040_bb0105) 2021; 28 Shu (10.1016/j.blre.2023.101040_bb0345) 2016; 23 Taduru (10.1016/j.blre.2023.101040_bb0370) 2017; 23 Hwa (10.1016/j.blre.2023.101040_bb0415) 2019; 33 López-Sainz (10.1016/j.blre.2023.101040_bb0150) 2021; 74 Cohen (10.1016/j.blre.2023.101040_bb0425) 2020; 136 Muchtar (10.1016/j.blre.2023.101040_bb0420) 2019; 33 Lilleness (10.1016/j.blre.2023.101040_bb0190) 2019; 133 Jimenez-Zepeda (10.1016/j.blre.2023.101040_bb0085) 2021; 21 Brink (10.1016/j.blre.2023.101040_bb0160) 2020 Kastritis (10.1016/j.blre.2023.101040_bb0405) 2020; 38 Mahmood (10.1016/j.blre.2023.101040_bb0410) 2014; 166 Abbink (10.1016/j.blre.2023.101040_bb0070) 2021; 138 Palladini (10.1016/j.blre.2023.101040_bb0120) 2020 Palladini (10.1016/j.blre.2023.101040_bb0065) 2021; 5 Nelson (10.1016/j.blre.2023.101040_bb0075) 2021; 138 Lousada (10.1016/j.blre.2023.101040_bb0380) 2020; 15 Gertz (10.1016/j.blre.2023.101040_bb0175) 2020; 324 Sidiqi (10.1016/j.blre.2023.101040_bb0440) 2020; 10 Wechalekar (10.1016/j.blre.2023.101040_bb0480) 2022; 1-15 Rosengren (10.1016/j.blre.2023.101040_bb0080) 2021 Acevedo (10.1016/j.blre.2023.101040_bb0195) 2019; 134 Palladini (10.1016/j.blre.2023.101040_bb0280) 2014; 124 Gertz (10.1016/j.blre.2023.101040_bb0220) 2018; 8 Palladini (10.1016/j.blre.2023.101040_bb0115) 2020; 136 Schulman (10.1016/j.blre.2023.101040_bb0180) 2020; 105 Wechalekar (10.1016/j.blre.2023.101040_bb0285) 2013; 121 Lane (10.1016/j.blre.2023.101040_bb0305) 2011; 118 Hemminki (10.1016/j.blre.2023.101040_bb0310) 2012; 12 McCausland (10.1016/j.blre.2023.101040_bb0335) 2017; 130 Bayliss (10.1016/j.blre.2023.101040_bb0340) 2017; 12 Rizzo (10.1016/j.blre.2023.101040_bb0100) 2021 Di Giovanni (10.1016/j.blre.2023.101040_bb0395) 2020; 36 Abdallah (10.1016/j.blre.2023.101040_bb0140) 2021; 5 Kumar (10.1016/j.blre.2023.101040_bb0295) 2012; 30 Michael (10.1016/j.blre.2023.101040_bb0320) 2010; 10 Angelini (10.1016/j.blre.2023.101040_bb0390) 2019; 13 Wechalekar (10.1016/j.blre.2023.101040_bb0025) 2015; 387 Palladini (10.1016/j.blre.2023.101040_bb0470) 2022; 34 Ravichandran (10.1016/j.blre.2023.101040_bb0165) 2020; 382 Zhang (10.1016/j.blre.2023.101040_bb0200) 2019; 19 Dispenzieri (10.1016/j.blre.2023.101040_bb0375) 2004; 22 Falk (10.1016/j.blre.2023.101040_bb0010) 2013; 164 Jiang (10.1016/j.blre.2023.101040_bb0230) 2018; 34 Quock (10.1016/j.blre.2023.101040_bb0360) 2019; 11 Escher (10.1016/j.blre.2023.101040_bb0145) 2020; 109 Dittrich (10.1016/j.blre.2023.101040_bb0185) 2019; 104 Kastritis (10.1016/j.blre.2023.101040_bb0300) 2012; 120 Palladini (10.1016/j.blre.2023.101040_bb0265) 2015; 126 Staron (10.1016/j.blre.2023.101040_bb0015) 2020; 10
References_xml	– volume: 36 start-page: 373 year: 2020 end-page: 383 ident: bb0395 article-title: Hiding in plain sight: cardiac amyloidosis, an emerging epidemic publication-title: Can J Cardiol – year: 2021 ident: bb0040 publication-title: Darzalex - European Medicines Agency [Internet] – volume: 124 start-page: 2325 year: 2014 end-page: 2332 ident: bb0280 article-title: A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis publication-title: Blood. – volume: 129 start-page: 2111 year: 2017 end-page: 2119 ident: bb0245 article-title: Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death publication-title: Blood. – volume: 32 start-page: 45 year: 1995 end-page: 59 ident: bb0020 article-title: Primary systemic amyloidosis: clinical and laboratory features in 474 cases publication-title: Semin Hematol – volume: 105 start-page: 495 year: 2020 end-page: 501 ident: bb0180 article-title: Patient outcomes in light chain (AL) amyloidosis: the clock is ticking from symptoms to diagnosis publication-title: Eur J Haematol – volume: 109 start-page: 78 year: 2020 end-page: 88 ident: bb0145 article-title: When and how do patients with cardiac amyloidosis die? publication-title: Clin Res Cardiol – volume: 166 start-page: 842 year: 2014 end-page: 848 ident: bb0410 article-title: Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens publication-title: Br J Haematol – volume: 188 start-page: 424 year: 2020 end-page: 427 ident: bb0130 article-title: Establishment of brain natriuretic peptide - based criteria for evaluating cardiac response to treatment in light chain (AL) amyloidosis publication-title: Br J Haematol – volume: 35 start-page: 916 year: 2021 end-page: 919 ident: bb0465 article-title: Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis publication-title: Leukemia. – volume: 128 start-page: 4448 year: 2016 ident: bb0255 article-title: Improved survival in al AMYLOIDOSIS: a POPULATION-BASED study on 1,430 patients diagnosed in Sweden 1995-2013 publication-title: Blood. – volume: 11 start-page: 207 year: 2017 end-page: 216 ident: bb0240 article-title: Light chain (AL) amyloidosis: the journey to diagnosis publication-title: The Patient – volume: 10 start-page: 56 year: 2010 end-page: 61 ident: bb0320 article-title: Clinical characteristics and outcome of primary systemic light-chain amyloidosis in Greece publication-title: Clin Lymphoma Myeloma Leuk – volume: 5 start-page: 477 year: 2021 end-page: 478 ident: bb0065 article-title: Real-world data on patient characteristics and treatment patterns for 3000 patients with systemic al amyloidosis in Europe between 2011 and 2018:A retrospective study by the European myeloma network publication-title: HemaSphere. – volume: 136 start-page: 16 year: 2020 end-page: 17 ident: bb0425 article-title: The prognostic importance of the 6-minute walk test in AL amyloidosis publication-title: Blood. – volume: 18 start-page: 139 year: 2017 end-page: 149 ident: bb0250 article-title: New and developing therapies for AL amyloidosis publication-title: Expert Opin Pharmacother – volume: 18 start-page: 604 year: 2011 end-page: 610 ident: bb0385 article-title: Peripheral nerve involvement in primary systemic AL amyloidosis: a clinical and electrophysiological study publication-title: Eur J Neurol – volume: 33 start-page: 811 year: 2019 end-page: 814 ident: bb0420 article-title: Comparative analysis of staging systems in AL amyloidosis publication-title: Leukemia. – volume: 15 year: 2015 ident: bb0260 article-title: Interim analysis of ALCHemy – a prospective study of 1000 patients with SYSTEMIC al amyloidosis publication-title: Clin Lymphoma Myeloma Leuk – volume: 103 start-page: 1065 year: 2017 end-page: 1072 ident: bb0030 article-title: Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response publication-title: Heart. – volume: 28 start-page: 211 year: 2021 end-page: 212 ident: bb0105 article-title: Incidence of light chain amyloidosis in Florence metropolitan area, Italy: a population-based study publication-title: Amyloid – volume: 164 start-page: 748 year: 2013 end-page: 749 ident: bb0010 article-title: AL amyloidosis or multiple myeloma? An important distinction publication-title: Br J Haematol – volume: 138 start-page: 153 year: 2021 ident: bb0060 article-title: Systemic light chain amyloidosis across Europe: key outcomes from a retrospective study of 4500 patients publication-title: Blood. – volume: 21 year: 2021 ident: bb0085 article-title: Real-world treatment patterns, clinical outcomes, and healthcare resource utilization of individuals with light chain (AL) amyloidosis in Alberta, Canada: a population-based study publication-title: Clin Lymphoma Myeloma Leuk – volume: 28 start-page: 3 year: 2020 end-page: 11 ident: bb0125 article-title: Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis publication-title: Amyloid Int J Exp Clin Invest – volume: 2 start-page: 1046 year: 2018 end-page: 1053 ident: bb0225 article-title: Epidemiology of AL amyloidosis: a real-world study using US claims data publication-title: Blood Adv – volume: 33 start-page: 1017 year: 2017 end-page: 1031 ident: bb0445 article-title: Disease burden of systemic light-chain amyloidosis: a systematic literature review publication-title: Curr Med Res Opin – volume: 126 start-page: 190 year: 2015 ident: bb0270 article-title: Accurate risk stratification IDENTIFIES patients with AL AMYLOIDOSIS benefiting most from UPFRONT Bortezomib combinations: a study of treatment outcomes in 984 patients publication-title: Blood. – volume: 7 start-page: 549 year: 2018 end-page: 559 ident: bb0365 article-title: Healthcare resource utilization and costs in amyloid light-chain amyloidosis: a real-world study using US claims data publication-title: J Comp Effect Res – volume: 12 year: 2017 ident: bb0340 article-title: The burden of amyloid light chain amyloidosis on health-related quality of life publication-title: Orphanet J Rare Dis – volume: 19 year: 2019 ident: bb0200 article-title: Estimating the global epidemiology of amyloid light-chain amyloidosis with an incidence-to-prevalence model publication-title: Clin Lymphoma Myeloma Leuk – volume: 10 year: 2020 ident: bb0015 article-title: Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities. Blood publication-title: Cancer J – volume: 138 start-page: 155 year: 2021 ident: bb0090 article-title: A 40-year natural history study of overall survival and primary causes of death in systemic light chain (AL) amyloidosis publication-title: Blood. – volume: 25 start-page: 227 year: 2018 end-page: 233 ident: bb0210 article-title: Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016 publication-title: Amyloid – volume: 94 start-page: 465 year: 2019 end-page: 471 ident: bb0205 article-title: Incidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015 publication-title: Mayo Clin Proc – volume: 11 start-page: 430 year: 2018 end-page: 437 ident: bb0050 article-title: Treatment tolerability in patients with immunoglobulin light-chain amyloidosis publication-title: Am Health Drug Benefits – volume: 128 start-page: 3586 year: 2016 ident: bb0350 article-title: Changes in health-related quality of life corresponding to hematologic responses to treatment in AL amyloidosis publication-title: Blood – volume: 118 start-page: 992 year: 2011 ident: bb0305 article-title: ALchemy - a large PROSPECTIVE ‘real World’ study of chemotherapy in AL amyloidosis publication-title: Blood. – year: 2021 ident: bb0035 publication-title: FDA grants accelerated approval to Darzalex Faspro for amyloidosis [Internet] – volume: 40 year: 2020 ident: bb0430 article-title: New developments in diagnosis, risk assessment and management in systemic amyloidosis publication-title: Blood Rev – volume: 11 year: 2021 ident: bb0045 article-title: Comprehensive review of AL amyloidosis: some practical recommendations. Blood publication-title: Cancer J – volume: 382 start-page: 1567 year: 2020 end-page: 1568 ident: bb0165 article-title: Epidemiologic and survival trends in amyloidosis, 1987-2019 publication-title: N Engl J Med – volume: 38 start-page: 3252 year: 2020 end-page: 3260 ident: bb0405 article-title: Bortezomib, Melphalan, and dexamethasone for light-chain amyloidosis publication-title: J Clin Oncol Off J Am Soc Clin Oncol – volume: 104 start-page: 1451 year: 2019 end-page: 1459 ident: bb0185 article-title: Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia publication-title: Haematologica. – volume: 23 start-page: 188 year: 2016 end-page: 193 ident: bb0345 article-title: Depression and anxiety in patients with AL amyloidosis as assessed by the SF-36 questionnaire: experience in 1226 patients publication-title: Amyloid – volume: 126 start-page: 612 year: 2015 end-page: 615 ident: bb0265 article-title: A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis publication-title: Blood. – volume: 36 start-page: 727 year: 2020 end-page: 734 ident: bb0355 article-title: Trends, burden, and impact of arrhythmia on cardiac amyloid patients: a 16-year nationwide study from 1999 to 2014 publication-title: J Arrhythm – volume: 10 year: 2020 ident: bb0460 article-title: Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy publication-title: Blood Cancer J – volume: 12 start-page: 974 year: 2012 ident: bb0310 article-title: Incidence and survival in non-hereditary amyloidosis in Sweden publication-title: BMC Public Health – volume: 11 start-page: 139 year: 2021 ident: bb0095 article-title: Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study publication-title: Blood Cancer J – volume: 133 start-page: 215 year: 2019 end-page: 223 ident: bb0190 article-title: Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis publication-title: Blood. – volume: 34 start-page: 216 year: 2018 end-page: 226 ident: bb0230 article-title: The effect and safety of Bortezomib in the treatment of AL amyloidosis: a systematic review and Meta-analysis publication-title: Indian J Hematol Blood Transfus – year: 2020 ident: bb0120 article-title: Real-world management of patients with systemic light chain amyloidosis in Europe: A retrospective observational multicenter study by European myeloma network (EMN) – start-page: EP1024 year: 2020 ident: bb0160 article-title: A Nationwide, population-based register of systemic Al amyloidosis patients in the Netherlands; preliminary results of 205 patients diagnosed in 2017 and 2018 publication-title: Eur Hematol Assoc – volume: 20 year: 2017 ident: bb0330 article-title: Health-related quality of life and rates of emergency room visits and hospitalization in patients with al amyloidosis: a prospective analysis publication-title: Value Health – start-page: 21 year: 2021 ident: bb0080 article-title: P-025: population-based incidence and survival of AL amyloidosis in Sweden publication-title: Clin Lymphoma Myeloma Leuk – volume: 120 start-page: 1786 year: 2012 ident: bb0300 article-title: Outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with novel agents and the importance of risk adapted treatment strategies publication-title: Blood – volume: 39 year: 2018 ident: bb0215 article-title: Incidence and prevalence of light chain amyloidosis: a population-based study publication-title: Eur Heart J – volume: 30 start-page: 989 year: 2012 end-page: 995 ident: bb0295 article-title: Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements publication-title: J Clin Oncol – volume: 136 start-page: 50 year: 2020 end-page: 51 ident: bb0115 article-title: First glimpse on real-world efficacy outcomes for 2000 patients with SYSTEMIC light chain AMYLOIDOSIS in Europe: a retrospective observational multicenter study by the European myeloma network publication-title: Blood – volume: 130 start-page: 4733 year: 2017 ident: bb0335 article-title: Associations between socioeconomic status and health-related quality of life in patients with AL amyloidosis publication-title: Blood. – volume: 161 start-page: 525 year: 2013 end-page: 532 ident: bb0290 article-title: Systemic amyloidosis in England: an epidemiological study publication-title: Br J Haematol – volume: 5 start-page: 1029 year: 2021 end-page: 1036 ident: bb0140 article-title: Prognostic restaging after treatment initiation in patients with AL amyloidosis publication-title: Blood Adv – volume: 6 year: 2009 ident: bb0055 article-title: Preferred reporting items for systematic reviews and Meta-analyses: the PRISMA statement publication-title: PLoS Med – volume: 387 start-page: 2641 year: 2015 end-page: 2654 ident: bb0025 article-title: Systemic amyloidosis publication-title: Lancet (London, England) – volume: 5 start-page: 467 year: 2021 end-page: 468 ident: bb0110 article-title: Pulmonary function tests reveal unrecognized lung dysfunction and have independent prognostic significance in patients with systemic al amyloidosis publication-title: HemaSphere. – volume: 17 start-page: 122 year: 2010 ident: bb0325 article-title: Systemic AL amyloidosis with renal involvement in a region of Western France publication-title: Amyloid. – volume: 349 start-page: 583 year: 2003 end-page: 596 ident: bb0005 article-title: Molecular mechanisms of amyloidosis publication-title: N Engl J Med – volume: 15 year: 2020 ident: bb0380 article-title: The amyloidosis forum: a public private partnership to advance drug development in al amyloidosis publication-title: Orphanet J Rare Dis – volume: 138 start-page: S366 year: 2010 ident: bb0315 article-title: Hepatic Al amyloidosis - a 10-year experience at the United Kingdom National Amyloidosis Centre (NAC) publication-title: Gastroenterology. – volume: 106 start-page: 340 year: 2021 end-page: 345 ident: bb0135 article-title: The impact of COVID-19 in the management of AL amyloidosis and immunoglobulin deposition disease: a single-center experience publication-title: Eur J Haematol – volume: 22 start-page: 3751 year: 2004 end-page: 3757 ident: bb0375 article-title: Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis publication-title: J Clin Oncol – volume: 138 start-page: 482 year: 2021 ident: bb0075 article-title: Autologous hematopoietic stem cell transplantation for AL amyloidosis refractory to induction therapy publication-title: Blood. – volume: 33 start-page: 1268 year: 2019 end-page: 1272 ident: bb0415 article-title: Prognostic restaging at the time of SECOND-LINE therapy in patients with al amyloidosis publication-title: Leukemia. – volume: 6 year: 2022 ident: bb0475 article-title: Summary of the EHA-ISA working group guidelines for high-dose chemotherapy and stem cell transplantation for systemic AL amyloidosis publication-title: Hemasphere. – volume: 23 year: 2017 ident: bb0370 article-title: Trends of cardiac transplantation in cardiac AMYLOIDOSIS in the United States FROM 2008–2014 publication-title: J Card Fail – volume: 1-15 year: 2022 ident: bb0480 article-title: Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group publication-title: Amyloid. – volume: 25 start-page: 1 year: 2018 end-page: 7 ident: bb0455 article-title: Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis publication-title: Amyloid – volume: 136 start-page: 2620 year: 2020 end-page: 2627 ident: bb0450 article-title: Management of AL amyloidosis in 2020 publication-title: Blood. – volume: 8 year: 2018 ident: bb0220 article-title: Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm. Blood publication-title: Cancer J – volume: 121 start-page: 3420 year: 2013 end-page: 3427 ident: bb0285 article-title: A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis publication-title: Blood – volume: 3 start-page: 1262 year: 2022 end-page: 1269 ident: bb0485 article-title: Understanding real-world treatment patterns and clinical outcomes in AL amyloidosis patients diagnosed in Canada: a population-based cohort study publication-title: eJHaem. – volume: 138 start-page: 2703 year: 2021 ident: bb0070 article-title: Prognostic relevance of cytogenetic chromosomal abnormalities on outcome among AL amyloidosis patients in the Netherlands publication-title: Blood. – volume: 13 start-page: 73 year: 2019 end-page: 90 ident: bb0390 article-title: Cardiac amyloidosis: a review of the literature and a practical approach for the clinicians publication-title: Italian J Med – volume: 36 start-page: 447 year: 2020 end-page: 449 ident: bb0170 article-title: An urgent need for data to drive decision making: rationale for the Canadian registry for amyloidosis research publication-title: Can J Cardiol – start-page: PB1657 year: 2021 ident: bb0100 article-title: AL amyloidosis survival evolution in new agents era: a real life experience publication-title: Eur Hematol Assoc – volume: 4 start-page: 38 year: 2018 ident: bb0235 article-title: Systemic immunoglobulin light chain amyloidosis publication-title: Nat Rev Dis Primers – volume: 34 start-page: 748 year: 2022 end-page: 756 ident: bb0470 article-title: Advances in the treatment of light chain amyloidosis publication-title: Curr Opin Oncol – volume: 134 start-page: 5447 year: 2019 ident: bb0195 article-title: Clinical characteristics, treatment regimens and survival in elderly patients with AL amyloidosis in a tertiary referral center publication-title: Blood. – volume: 10 start-page: 55 year: 2020 ident: bb0440 article-title: Venetoclax for the treatment of translocation (11;14) AL amyloidosis publication-title: Blood Cancer – year: 2021 ident: bb0435 article-title: IMW Meeting Materials 2021 [Internet]. International Myeloma Society – volume: 385 start-page: 46 year: 2021 end-page: 58 ident: bb0400 article-title: Daratumumab-based treatment for immunoglobulin light-chain amyloidosis publication-title: N Engl J Med – volume: 100 start-page: 511 year: 2015 end-page: 512 ident: bb0275 article-title: Al amyloidosis and quality of life outcomes publication-title: Haematologica. – volume: 11 start-page: 431 year: 2019 end-page: 439 ident: bb0360 article-title: Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States publication-title: CEOR – volume: 324 start-page: 79 year: 2020 end-page: 89 ident: bb0175 article-title: Systemic amyloidosis recognition, prognosis, and therapy: a systematic review publication-title: JAMA. – volume: 74 start-page: 149 year: 2021 end-page: 158 ident: bb0150 article-title: Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center publication-title: Revista espanola de cardiologia (English ed) – volume: 106 start-page: 354 year: 2020 end-page: 361 ident: bb0155 article-title: Characterization and prognostic implication of delayed complete response in al amyloidosis publication-title: Eur J Haematol – year: 2020 ident: 10.1016/j.blre.2023.101040_bb0120 – volume: 104 start-page: 1451 issue: 7 year: 2019 ident: 10.1016/j.blre.2023.101040_bb0185 article-title: Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia publication-title: Haematologica. doi: 10.3324/haematol.2018.205336 – volume: 5 start-page: 477 issue: 2 year: 2021 ident: 10.1016/j.blre.2023.101040_bb0065 article-title: Real-world data on patient characteristics and treatment patterns for 3000 patients with systemic al amyloidosis in Europe between 2011 and 2018:A retrospective study by the European myeloma network publication-title: HemaSphere. – volume: 382 start-page: 1567 issue: 16 year: 2020 ident: 10.1016/j.blre.2023.101040_bb0165 article-title: Epidemiologic and survival trends in amyloidosis, 1987-2019 publication-title: N Engl J Med doi: 10.1056/NEJMc1917321 – volume: 100 start-page: 511 issue: 0 year: 2015 ident: 10.1016/j.blre.2023.101040_bb0275 article-title: Al amyloidosis and quality of life outcomes publication-title: Haematologica. – volume: 10 start-page: 56 issue: 1 year: 2010 ident: 10.1016/j.blre.2023.101040_bb0320 article-title: Clinical characteristics and outcome of primary systemic light-chain amyloidosis in Greece publication-title: Clin Lymphoma Myeloma Leuk doi: 10.3816/CLML.2010.n.006 – volume: 33 start-page: 1017 issue: 6 year: 2017 ident: 10.1016/j.blre.2023.101040_bb0445 article-title: Disease burden of systemic light-chain amyloidosis: a systematic literature review publication-title: Curr Med Res Opin doi: 10.1080/03007995.2017.1297930 – volume: 124 start-page: 2325 issue: 15 year: 2014 ident: 10.1016/j.blre.2023.101040_bb0280 article-title: A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis publication-title: Blood. doi: 10.1182/blood-2014-04-570010 – volume: 130 start-page: 4733 issue: Supplement 1 year: 2017 ident: 10.1016/j.blre.2023.101040_bb0335 article-title: Associations between socioeconomic status and health-related quality of life in patients with AL amyloidosis publication-title: Blood. – volume: 23 issue: 8 year: 2017 ident: 10.1016/j.blre.2023.101040_bb0370 article-title: Trends of cardiac transplantation in cardiac AMYLOIDOSIS in the United States FROM 2008–2014 publication-title: J Card Fail doi: 10.1016/j.cardfail.2017.07.365 – volume: 134 start-page: 5447 issue: Supplement_1 year: 2019 ident: 10.1016/j.blre.2023.101040_bb0195 article-title: Clinical characteristics, treatment regimens and survival in elderly patients with AL amyloidosis in a tertiary referral center publication-title: Blood. doi: 10.1182/blood-2019-124980 – volume: 11 start-page: 431 year: 2019 ident: 10.1016/j.blre.2023.101040_bb0360 article-title: Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States publication-title: CEOR doi: 10.2147/CEOR.S207127 – volume: 138 start-page: 153 issue: Supplement 1 year: 2021 ident: 10.1016/j.blre.2023.101040_bb0060 article-title: Systemic light chain amyloidosis across Europe: key outcomes from a retrospective study of 4500 patients publication-title: Blood. doi: 10.1182/blood-2021-152675 – volume: 74 start-page: 149 issue: 2 year: 2021 ident: 10.1016/j.blre.2023.101040_bb0150 article-title: Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center publication-title: Revista espanola de cardiologia (English ed) doi: 10.1016/j.recesp.2019.12.017 – volume: 33 start-page: 1268 issue: 5 year: 2019 ident: 10.1016/j.blre.2023.101040_bb0415 article-title: Prognostic restaging at the time of SECOND-LINE therapy in patients with al amyloidosis publication-title: Leukemia. doi: 10.1038/s41375-019-0400-5 – volume: 136 start-page: 16 issue: Supplement 1 year: 2020 ident: 10.1016/j.blre.2023.101040_bb0425 article-title: The prognostic importance of the 6-minute walk test in AL amyloidosis publication-title: Blood. doi: 10.1182/blood-2020-137036 – volume: 34 start-page: 748 issue: 6 year: 2022 ident: 10.1016/j.blre.2023.101040_bb0470 article-title: Advances in the treatment of light chain amyloidosis publication-title: Curr Opin Oncol doi: 10.1097/CCO.0000000000000881 – volume: 138 start-page: S366 issue: 5 year: 2010 ident: 10.1016/j.blre.2023.101040_bb0315 article-title: Hepatic Al amyloidosis - a 10-year experience at the United Kingdom National Amyloidosis Centre (NAC) publication-title: Gastroenterology. doi: 10.1016/S0016-5085(10)61689-7 – volume: 30 start-page: 989 issue: 9 year: 2012 ident: 10.1016/j.blre.2023.101040_bb0295 article-title: Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements publication-title: J Clin Oncol doi: 10.1200/JCO.2011.38.5724 – volume: 19 issue: 10 year: 2019 ident: 10.1016/j.blre.2023.101040_bb0200 article-title: Estimating the global epidemiology of amyloid light-chain amyloidosis with an incidence-to-prevalence model publication-title: Clin Lymphoma Myeloma Leuk doi: 10.1016/j.clml.2019.09.558 – volume: 121 start-page: 3420 issue: 17 year: 2013 ident: 10.1016/j.blre.2023.101040_bb0285 article-title: A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis publication-title: Blood doi: 10.1182/blood-2012-12-473066 – volume: 25 start-page: 1 issue: 1 year: 2018 ident: 10.1016/j.blre.2023.101040_bb0455 article-title: Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis publication-title: Amyloid doi: 10.1080/13506129.2017.1411796 – volume: 5 start-page: 467 issue: 2 year: 2021 ident: 10.1016/j.blre.2023.101040_bb0110 article-title: Pulmonary function tests reveal unrecognized lung dysfunction and have independent prognostic significance in patients with systemic al amyloidosis publication-title: HemaSphere. – volume: 7 start-page: 549 issue: 6 year: 2018 ident: 10.1016/j.blre.2023.101040_bb0365 article-title: Healthcare resource utilization and costs in amyloid light-chain amyloidosis: a real-world study using US claims data publication-title: J Comp Effect Res doi: 10.2217/cer-2017-0100 – volume: 18 start-page: 604 issue: 4 year: 2011 ident: 10.1016/j.blre.2023.101040_bb0385 article-title: Peripheral nerve involvement in primary systemic AL amyloidosis: a clinical and electrophysiological study publication-title: Eur J Neurol doi: 10.1111/j.1468-1331.2010.03215.x – volume: 40 year: 2020 ident: 10.1016/j.blre.2023.101040_bb0430 article-title: New developments in diagnosis, risk assessment and management in systemic amyloidosis publication-title: Blood Rev doi: 10.1016/j.blre.2019.100636 – volume: 36 start-page: 727 issue: 4 year: 2020 ident: 10.1016/j.blre.2023.101040_bb0355 article-title: Trends, burden, and impact of arrhythmia on cardiac amyloid patients: a 16-year nationwide study from 1999 to 2014 publication-title: J Arrhythm doi: 10.1002/joa3.12376 – volume: 38 start-page: 3252 issue: 28 year: 2020 ident: 10.1016/j.blre.2023.101040_bb0405 article-title: Bortezomib, Melphalan, and dexamethasone for light-chain amyloidosis publication-title: J Clin Oncol Off J Am Soc Clin Oncol doi: 10.1200/JCO.20.01285 – volume: 164 start-page: 748 issue: 5 year: 2013 ident: 10.1016/j.blre.2023.101040_bb0010 article-title: AL amyloidosis or multiple myeloma? An important distinction publication-title: Br J Haematol doi: 10.1111/bjh.12677 – volume: 166 start-page: 842 issue: 6 year: 2014 ident: 10.1016/j.blre.2023.101040_bb0410 article-title: Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens publication-title: Br J Haematol doi: 10.1111/bjh.12973 – year: 2021 ident: 10.1016/j.blre.2023.101040_bb0035 – volume: 22 start-page: 3751 issue: 18 year: 2004 ident: 10.1016/j.blre.2023.101040_bb0375 article-title: Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis publication-title: J Clin Oncol doi: 10.1200/JCO.2004.03.029 – volume: 11 issue: 5 year: 2021 ident: 10.1016/j.blre.2023.101040_bb0045 article-title: Comprehensive review of AL amyloidosis: some practical recommendations. Blood publication-title: Cancer J – volume: 138 start-page: 482 issue: Supplement 1 year: 2021 ident: 10.1016/j.blre.2023.101040_bb0075 article-title: Autologous hematopoietic stem cell transplantation for AL amyloidosis refractory to induction therapy publication-title: Blood. doi: 10.1182/blood-2021-154277 – volume: 324 start-page: 79 issue: 1 year: 2020 ident: 10.1016/j.blre.2023.101040_bb0175 article-title: Systemic amyloidosis recognition, prognosis, and therapy: a systematic review publication-title: JAMA. doi: 10.1001/jama.2020.5493 – start-page: EP1024 year: 2020 ident: 10.1016/j.blre.2023.101040_bb0160 article-title: A Nationwide, population-based register of systemic Al amyloidosis patients in the Netherlands; preliminary results of 205 patients diagnosed in 2017 and 2018 publication-title: Eur Hematol Assoc – year: 2021 ident: 10.1016/j.blre.2023.101040_bb0040 – volume: 3 start-page: 1262 issue: 4 year: 2022 ident: 10.1016/j.blre.2023.101040_bb0485 article-title: Understanding real-world treatment patterns and clinical outcomes in AL amyloidosis patients diagnosed in Canada: a population-based cohort study publication-title: eJHaem. doi: 10.1002/jha2.562 – volume: 33 start-page: 811 issue: 3 year: 2019 ident: 10.1016/j.blre.2023.101040_bb0420 article-title: Comparative analysis of staging systems in AL amyloidosis publication-title: Leukemia. doi: 10.1038/s41375-018-0370-z – volume: 17 start-page: 122 issue: Suppl. 1 year: 2010 ident: 10.1016/j.blre.2023.101040_bb0325 article-title: Systemic AL amyloidosis with renal involvement in a region of Western France publication-title: Amyloid. – volume: 35 start-page: 916 issue: 3 year: 2021 ident: 10.1016/j.blre.2023.101040_bb0465 article-title: Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis publication-title: Leukemia. doi: 10.1038/s41375-020-1006-7 – volume: 2 start-page: 1046 issue: 10 year: 2018 ident: 10.1016/j.blre.2023.101040_bb0225 article-title: Epidemiology of AL amyloidosis: a real-world study using US claims data publication-title: Blood Adv doi: 10.1182/bloodadvances.2018016402 – volume: 5 start-page: 1029 issue: 4 year: 2021 ident: 10.1016/j.blre.2023.101040_bb0140 article-title: Prognostic restaging after treatment initiation in patients with AL amyloidosis publication-title: Blood Adv doi: 10.1182/bloodadvances.2020003782 – volume: 128 start-page: 3586 issue: 22 year: 2016 ident: 10.1016/j.blre.2023.101040_bb0350 article-title: Changes in health-related quality of life corresponding to hematologic responses to treatment in AL amyloidosis publication-title: Blood doi: 10.1182/blood.V128.22.3586.3586 – volume: 1-15 year: 2022 ident: 10.1016/j.blre.2023.101040_bb0480 article-title: Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group publication-title: Amyloid. – volume: 138 start-page: 155 year: 2021 ident: 10.1016/j.blre.2023.101040_bb0090 article-title: A 40-year natural history study of overall survival and primary causes of death in systemic light chain (AL) amyloidosis publication-title: Blood. doi: 10.1182/blood-2021-151804 – volume: 20 issue: 9 year: 2017 ident: 10.1016/j.blre.2023.101040_bb0330 article-title: Health-related quality of life and rates of emergency room visits and hospitalization in patients with al amyloidosis: a prospective analysis publication-title: Value Health doi: 10.1016/j.jval.2017.08.927 – volume: 105 start-page: 495 issue: 4 year: 2020 ident: 10.1016/j.blre.2023.101040_bb0180 article-title: Patient outcomes in light chain (AL) amyloidosis: the clock is ticking from symptoms to diagnosis publication-title: Eur J Haematol doi: 10.1111/ejh.13472 – volume: 129 start-page: 2111 issue: 15 year: 2017 ident: 10.1016/j.blre.2023.101040_bb0245 article-title: Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death publication-title: Blood. doi: 10.1182/blood-2016-11-751628 – volume: 36 start-page: 373 issue: 3 year: 2020 ident: 10.1016/j.blre.2023.101040_bb0395 article-title: Hiding in plain sight: cardiac amyloidosis, an emerging epidemic publication-title: Can J Cardiol – volume: 15 issue: 1 year: 2020 ident: 10.1016/j.blre.2023.101040_bb0380 article-title: The amyloidosis forum: a public private partnership to advance drug development in al amyloidosis publication-title: Orphanet J Rare Dis – volume: 10 issue: 8 year: 2020 ident: 10.1016/j.blre.2023.101040_bb0460 article-title: Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy publication-title: Blood Cancer J doi: 10.1038/s41408-020-00355-6 – volume: 28 start-page: 3 issue: 1 year: 2020 ident: 10.1016/j.blre.2023.101040_bb0125 article-title: Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis publication-title: Amyloid Int J Exp Clin Invest – volume: 11 start-page: 207 issue: 2 year: 2017 ident: 10.1016/j.blre.2023.101040_bb0240 article-title: Light chain (AL) amyloidosis: the journey to diagnosis publication-title: The Patient doi: 10.1007/s40271-017-0273-5 – volume: 120 start-page: 1786 issue: 21 year: 2012 ident: 10.1016/j.blre.2023.101040_bb0300 article-title: Outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with novel agents and the importance of risk adapted treatment strategies publication-title: Blood doi: 10.1182/blood.V120.21.1786.1786 – volume: 109 start-page: 78 issue: 1 year: 2020 ident: 10.1016/j.blre.2023.101040_bb0145 article-title: When and how do patients with cardiac amyloidosis die? publication-title: Clin Res Cardiol doi: 10.1007/s00392-019-01490-2 – volume: 188 start-page: 424 issue: 3 year: 2020 ident: 10.1016/j.blre.2023.101040_bb0130 article-title: Establishment of brain natriuretic peptide - based criteria for evaluating cardiac response to treatment in light chain (AL) amyloidosis publication-title: Br J Haematol doi: 10.1111/bjh.16198 – volume: 126 start-page: 612 issue: 5 year: 2015 ident: 10.1016/j.blre.2023.101040_bb0265 article-title: A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis publication-title: Blood. doi: 10.1182/blood-2015-01-620302 – volume: 349 start-page: 583 issue: 6 year: 2003 ident: 10.1016/j.blre.2023.101040_bb0005 article-title: Molecular mechanisms of amyloidosis publication-title: N Engl J Med doi: 10.1056/NEJMra023144 – start-page: PB1657 year: 2021 ident: 10.1016/j.blre.2023.101040_bb0100 article-title: AL amyloidosis survival evolution in new agents era: a real life experience publication-title: Eur Hematol Assoc – volume: 385 start-page: 46 issue: 1 year: 2021 ident: 10.1016/j.blre.2023.101040_bb0400 article-title: Daratumumab-based treatment for immunoglobulin light-chain amyloidosis publication-title: N Engl J Med doi: 10.1056/NEJMoa2028631 – volume: 12 start-page: 974 year: 2012 ident: 10.1016/j.blre.2023.101040_bb0310 article-title: Incidence and survival in non-hereditary amyloidosis in Sweden publication-title: BMC Public Health doi: 10.1186/1471-2458-12-974 – volume: 94 start-page: 465 issue: 3 year: 2019 ident: 10.1016/j.blre.2023.101040_bb0205 article-title: Incidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015 publication-title: Mayo Clin Proc doi: 10.1016/j.mayocp.2018.08.041 – volume: 106 start-page: 340 issue: 3 year: 2021 ident: 10.1016/j.blre.2023.101040_bb0135 article-title: The impact of COVID-19 in the management of AL amyloidosis and immunoglobulin deposition disease: a single-center experience publication-title: Eur J Haematol doi: 10.1111/ejh.13552 – volume: 34 start-page: 216 issue: 2 year: 2018 ident: 10.1016/j.blre.2023.101040_bb0230 article-title: The effect and safety of Bortezomib in the treatment of AL amyloidosis: a systematic review and Meta-analysis publication-title: Indian J Hematol Blood Transfus doi: 10.1007/s12288-018-0937-x – volume: 138 start-page: 2703 issue: Supplement 1 year: 2021 ident: 10.1016/j.blre.2023.101040_bb0070 article-title: Prognostic relevance of cytogenetic chromosomal abnormalities on outcome among AL amyloidosis patients in the Netherlands publication-title: Blood. doi: 10.1182/blood-2021-152099 – start-page: 21 year: 2021 ident: 10.1016/j.blre.2023.101040_bb0080 article-title: P-025: population-based incidence and survival of AL amyloidosis in Sweden publication-title: Clin Lymphoma Myeloma Leuk – volume: 12 issue: 1 year: 2017 ident: 10.1016/j.blre.2023.101040_bb0340 article-title: The burden of amyloid light chain amyloidosis on health-related quality of life publication-title: Orphanet J Rare Dis doi: 10.1186/s13023-016-0564-2 – volume: 10 issue: 11 year: 2020 ident: 10.1016/j.blre.2023.101040_bb0015 article-title: Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities. Blood publication-title: Cancer J – volume: 118 start-page: 992 issue: 21 year: 2011 ident: 10.1016/j.blre.2023.101040_bb0305 article-title: ALchemy - a large PROSPECTIVE ‘real World’ study of chemotherapy in AL amyloidosis publication-title: Blood. doi: 10.1182/blood.V118.21.992.992 – volume: 13 start-page: 73 issue: 2 year: 2019 ident: 10.1016/j.blre.2023.101040_bb0390 article-title: Cardiac amyloidosis: a review of the literature and a practical approach for the clinicians publication-title: Italian J Med doi: 10.4081/itjm.2019.1149 – volume: 32 start-page: 45 issue: 1 year: 1995 ident: 10.1016/j.blre.2023.101040_bb0020 article-title: Primary systemic amyloidosis: clinical and laboratory features in 474 cases publication-title: Semin Hematol – volume: 126 start-page: 190 issue: 23 year: 2015 ident: 10.1016/j.blre.2023.101040_bb0270 article-title: Accurate risk stratification IDENTIFIES patients with AL AMYLOIDOSIS benefiting most from UPFRONT Bortezomib combinations: a study of treatment outcomes in 984 patients publication-title: Blood. doi: 10.1182/blood.V126.23.190.190 – volume: 387 start-page: 2641 issue: 10038 year: 2015 ident: 10.1016/j.blre.2023.101040_bb0025 article-title: Systemic amyloidosis publication-title: Lancet (London, England) doi: 10.1016/S0140-6736(15)01274-X – volume: 28 start-page: 211 issue: 3 year: 2021 ident: 10.1016/j.blre.2023.101040_bb0105 article-title: Incidence of light chain amyloidosis in Florence metropolitan area, Italy: a population-based study publication-title: Amyloid doi: 10.1080/13506129.2021.1898365 – volume: 106 start-page: 354 issue: 3 year: 2020 ident: 10.1016/j.blre.2023.101040_bb0155 article-title: Characterization and prognostic implication of delayed complete response in al amyloidosis publication-title: Eur J Haematol doi: 10.1111/ejh.13554 – volume: 6 issue: 2 year: 2022 ident: 10.1016/j.blre.2023.101040_bb0475 article-title: Summary of the EHA-ISA working group guidelines for high-dose chemotherapy and stem cell transplantation for systemic AL amyloidosis publication-title: Hemasphere. doi: 10.1097/HS9.0000000000000681 – volume: 21 year: 2021 ident: 10.1016/j.blre.2023.101040_bb0085 article-title: Real-world treatment patterns, clinical outcomes, and healthcare resource utilization of individuals with light chain (AL) amyloidosis in Alberta, Canada: a population-based study publication-title: Clin Lymphoma Myeloma Leuk doi: 10.1016/S2152-2650(21)02153-4 – volume: 11 start-page: 139 issue: 8 year: 2021 ident: 10.1016/j.blre.2023.101040_bb0095 article-title: Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study publication-title: Blood Cancer J doi: 10.1038/s41408-021-00529-w – volume: 4 start-page: 38 issue: 1 year: 2018 ident: 10.1016/j.blre.2023.101040_bb0235 article-title: Systemic immunoglobulin light chain amyloidosis publication-title: Nat Rev Dis Primers doi: 10.1038/s41572-018-0034-3 – volume: 161 start-page: 525 issue: 4 year: 2013 ident: 10.1016/j.blre.2023.101040_bb0290 article-title: Systemic amyloidosis in England: an epidemiological study publication-title: Br J Haematol doi: 10.1111/bjh.12286 – volume: 15 year: 2015 ident: 10.1016/j.blre.2023.101040_bb0260 article-title: Interim analysis of ALCHemy – a prospective study of 1000 patients with SYSTEMIC al amyloidosis publication-title: Clin Lymphoma Myeloma Leuk doi: 10.1016/j.clml.2015.07.201 – volume: 10 start-page: 55 issue: 5 year: 2020 ident: 10.1016/j.blre.2023.101040_bb0440 article-title: Venetoclax for the treatment of translocation (11;14) AL amyloidosis publication-title: Blood Cancer doi: 10.1038/s41408-020-0321-6 – volume: 18 start-page: 139 issue: 2 year: 2017 ident: 10.1016/j.blre.2023.101040_bb0250 article-title: New and developing therapies for AL amyloidosis publication-title: Expert Opin Pharmacother doi: 10.1080/14656566.2016.1274971 – volume: 133 start-page: 215 issue: 3 year: 2019 ident: 10.1016/j.blre.2023.101040_bb0190 article-title: Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis publication-title: Blood. doi: 10.1182/blood-2018-06-858951 – volume: 25 start-page: 227 issue: 4 year: 2018 ident: 10.1016/j.blre.2023.101040_bb0210 article-title: Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016 publication-title: Amyloid doi: 10.1080/13506129.2018.1536043 – volume: 11 start-page: 430 year: 2018 ident: 10.1016/j.blre.2023.101040_bb0050 article-title: Treatment tolerability in patients with immunoglobulin light-chain amyloidosis publication-title: Am Health Drug Benefits – volume: 136 start-page: 2620 issue: 23 year: 2020 ident: 10.1016/j.blre.2023.101040_bb0450 article-title: Management of AL amyloidosis in 2020 publication-title: Blood. doi: 10.1182/blood.2020006913 – volume: 39 issue: Supplement 1 year: 2018 ident: 10.1016/j.blre.2023.101040_bb0215 article-title: Incidence and prevalence of light chain amyloidosis: a population-based study publication-title: Eur Heart J – volume: 136 start-page: 50 issue: Supplement 1 year: 2020 ident: 10.1016/j.blre.2023.101040_bb0115 article-title: First glimpse on real-world efficacy outcomes for 2000 patients with SYSTEMIC light chain AMYLOIDOSIS in Europe: a retrospective observational multicenter study by the European myeloma network publication-title: Blood doi: 10.1182/blood-2020-140708 – volume: 8 issue: 5 year: 2018 ident: 10.1016/j.blre.2023.101040_bb0220 article-title: Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm. Blood publication-title: Cancer J – volume: 103 start-page: 1065 issue: 14 year: 2017 ident: 10.1016/j.blre.2023.101040_bb0030 article-title: Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response publication-title: Heart. doi: 10.1136/heartjnl-2016-310704 – volume: 128 start-page: 4448 issue: 22 year: 2016 ident: 10.1016/j.blre.2023.101040_bb0255 article-title: Improved survival in al AMYLOIDOSIS: a POPULATION-BASED study on 1,430 patients diagnosed in Sweden 1995-2013 publication-title: Blood. doi: 10.1182/blood.V128.22.4448.4448 – volume: 23 start-page: 188 issue: 3 year: 2016 ident: 10.1016/j.blre.2023.101040_bb0345 article-title: Depression and anxiety in patients with AL amyloidosis as assessed by the SF-36 questionnaire: experience in 1226 patients publication-title: Amyloid doi: 10.1080/13506129.2016.1208081 – volume: 6 issue: 7 year: 2009 ident: 10.1016/j.blre.2023.101040_bb0055 article-title: Preferred reporting items for systematic reviews and Meta-analyses: the PRISMA statement publication-title: PLoS Med doi: 10.1371/journal.pmed.1000097 – volume: 36 start-page: 447 issue: 3 year: 2020 ident: 10.1016/j.blre.2023.101040_bb0170 article-title: An urgent need for data to drive decision making: rationale for the Canadian registry for amyloidosis research publication-title: Can J Cardiol
SSID	ssj0009367
Score	2.4519029
SecondaryResourceType	review_article
Snippet	Amyloidosis is the term to define a broad array of rare protein misfolding syndromes. Among them, light chain (AL) amyloidosis is the most common, affecting...
SourceID	proquest pubmed crossref elsevier
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	101040
SubjectTerms	AL amyloidosis Amyloidosis - diagnosis Amyloidosis - epidemiology Amyloidosis - etiology Epidemiology Humans Immunoglobulin Light-chain Amyloidosis - diagnosis Immunoglobulin Light-chain Amyloidosis - epidemiology Immunoglobulin Light-chain Amyloidosis - therapy Light-chain amyloidosis PRISMA guidelines Quality of Life Rare Diseases Risk Assessment Risk-staging Systematic literature review
Title	State-of-the-art review on AL amyloidosis in Western Countries: Epidemiology, health economics, risk assessment and therapeutic management of a rare disease
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S0268960X23000012 https://dx.doi.org/10.1016/j.blre.2023.101040 https://www.ncbi.nlm.nih.gov/pubmed/36697295 https://www.proquest.com/docview/2769996929
Volume	59
WOSCitedRecordID	wos000982686800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1532-1681 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009367 issn: 0268-960X databaseCode: AIEXJ dateStart: 19950301 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ba9swFBZpO8Zeyu5LtxUN9uZ6xJYt23sLI-s2ujJox_JmZFmmLplcnKSU_Zb9jf2_HVkXm4x2F9iLCcKKhL_P0jnyd85B6GWa8EAIQXwqwsSPCkJ9ZVb7SUm5YBkpKJt0xSaS4-N0Ps8-jUY_bCzM5SKRMr26yi7-K9TQBmCr0Nm_gNv9KTTAbwAdrgA7XP8I-M589JvKB9NO6d5cdIr0pkce-woeel02Kg9JLb0vOlFCF5quSmt1ArlZXzW2g0DHSnrCxDB3yHeSdObSelohpo3lMqpYpzTwWqUwG34Nsh-SlXDeTNGZ9ycM_PVGJ0RY1D33Ds_ESssPDmtVa8mt661KdmkCvZtWyG-NO2aA9jXntVG0VUzWbHjSEQ50hfr4zYbg9HqnZZc5FlZsOpnrDc2u4qEfUF0Lxi7zOvH4LzuGPrw4f1UsWpU1NSSqaaJTSG1k4j5RY6mhwG3rTvC20E6YxBnsBzvT97P5hz7bM-lKF7u5mWgtLSzcHOk6i-g6j6ezfE7vol3jsuCppto9NBLyPrr90YgyHqDvm4zDGk7cSDw9wgPG4VpiwzjsGPcaD_l2gDXbsGPbAVZcwz3XMHAND7iGe67hpsIMK65hw7WH6PPb2embd74p-uHzKA5WcE0mnJIqLsoyzSYkK2kRMVbGgeDwVGMeESrKQB0dCDDuOSxCUVqAn8hIHBSCkEdoWzZSPEE4KGC_AnO5isMqionIADNecpKljClXeYwC--BzbjLiq8Isi9xKH89zBVauwMo1WGPkuT4XOh_MjXcTi2duI51hb86BfDf2il0vYwdr-_a3_V5YyuSwSagvf0yKZr3Mw4SqFRhcoTF6rLnkZk8ozcDDjvf-cdSn6E7_sj5D26t2LZ6jW_xyVS_bfbSVzNN98378BNC28KU
linkProvider	Elsevier
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=State-of-the-art+review+on+AL+amyloidosis+in+Western+Countries%3A+Epidemiology%2C+health+economics%2C+risk+assessment+and+therapeutic+management+of+a+rare+disease&rft.jtitle=Blood+reviews&rft.au=Sabinot%2C+Alice&rft.au=Ghetti%2C+Gianni&rft.au=Pradelli%2C+Lorenzo&rft.au=Bellucci%2C+Stefania&rft.date=2023-05-01&rft.pub=Elsevier+Ltd&rft.issn=0268-960X&rft.eissn=1532-1681&rft.volume=59&rft_id=info:doi/10.1016%2Fj.blre.2023.101040&rft.externalDocID=S0268960X23000012
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0268-960X&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0268-960X&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0268-960X&client=summon